Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OVA-mRNA dendritic cell vaccine
- Development stage
- Preclinical
- Lead developer
- Duke University
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
OVA-mRNA dendritic cell vaccine is an experimental cancer immunotherapy consisting of dendritic cells (DCs) that have been ex vivo electroporated with mRNA encoding the model antigen ovalbumin (OVA). This vaccine is primarily used in preclinical research to study DC migration, antigen presentation, and T-cell activation in tumor models such as GL261-OVA glioblastoma. The mechanism involves the translation of the mRNA within the DCs, followed by the processing and presentation of OVA-derived peptides on MHC molecules to prime and expand antigen-specific CD8+ and CD4+ T cells. In research conducted at Duke University, it is often studied alongside adjuvants like CCL3 or tetanus-diphtheria (Td) preconditioning to enhance DC migration to draining lymph nodes and improve overall survival in established tumor models.
- Other names
- OVA-DCOVA-mRNA DC vaccine
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)H-2Kb
Beyond the preview
Go deeper on OVA-mRNA dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OVA-mRNA dendritic cell vaccine.